Agile Therapeutics to Report Second Quarter 2021 Financial Results and Provide Business Update on Monday, July 26, 2021

Rhea-AI Summary

Agile Therapeutics (Nasdaq: AGRX) will release its second quarter 2021 financial results on July 26, 2021, post-market. A live conference call will occur at 4:30 p.m. EDT, featuring dial-in options for both domestic and international investors. Interested parties can access the live stream and archived webcast through the company's website. Agile Therapeutics focuses on women's healthcare, offering innovative contraceptive solutions, including the non-daily prescription contraceptive, Twirla, utilizing their proprietary Skinfusion® technology.

Positive

• Agile Therapeutics scheduled a conference call to discuss second quarter 2021 financial results, indicating transparency and engagement with investors.

Negative

• None.

Live Conference Call and Webcast at 4:30 p.m. EDT

PRINCETON, N.J., July 01, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s healthcare company, today announced it will report second quarter 2021 financial results after the market close on Monday, July 26, 2021 as follows:

Date	Monday, July 26, 2021
Time	4:30 p.m. EDT
Webcast (live and archived)	Events & Presentations
Dial-in numbers	(833) 979-2857 (U.S. toll-free) or (236) 714-2948
Conference ID	1732729

Investors interested in listening to the conference call may do so by dialing (833) 979-2857 for domestic callers or (236) 714-2948 for international callers. A live webcast will be available in the Events and Presentations section of the Investor Relations page at https://ir.agiletherapeutics.com/events-and-presentations/, or by clicking here.
Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events and Presentations section of the company's website.

About Agile Therapeutics, Inc.
Agile Therapeutics is a forward-looking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our initial product, Twirla®, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to allow drug delivery through the skin. For more information, please visit the company website at www.agiletherapeutics.com. The Company may occasionally disseminate material, nonpublic information on the Company’s website.

Contact: 
Matt Riley
Head of Investor Relations & Corporate Communications
mriley@agiletherapeutics.com

FAQ

When will Agile Therapeutics report its second quarter 2021 financial results?

Agile Therapeutics will report its second quarter 2021 financial results on July 26, 2021, after the market close.

What time is the conference call for Agile Therapeutics second quarter results?

The conference call for Agile Therapeutics' second quarter results is scheduled for 4:30 p.m. EDT on July 26, 2021.

How can I access the webcast for Agile Therapeutics' financial results?

The webcast for Agile Therapeutics' financial results can be accessed via their Investor Relations page on their website.

What is Twirla?

Twirla is a non-daily prescription contraceptive developed by Agile Therapeutics, utilizing their proprietary Skinfusion® technology.